市况评论

作者

李乐雯女士 (Phoenix Li)
经理

现任职辉立分行经理,对股票、期货投资经验丰富。 乐意为客户提供投资分析及买卖策略。 欢迎各位来电交流心得。
电话:
29437400

国药控股 (1099.HK)

2019年5月14日 星期二 观看次数2380

1099 国药控股

SINOPHARM HOLDING CO LTD

Business Summary

Sinopharm Group Company Limited is principally engaged in the distribution of pharmaceutical products and medical equipment. The Company operates through three business segments.

The Pharmaceutical Distribution segment is engaged in the distribution of medicines, medicine devices and pharmaceutical products to hospitals, other distributors, retail drug stores and clinics.

The Retail Pharmacy segment is engaged in the operation of medicine chain stores. The Other Business segment is engaged in the distribution of laboratory supplies, the manufacture and distribution of chemical reagents, as well as the production and sales of pharmaceutical products.

The Company is also engaged in the provision of pharmaceutical logistics services and property rental business in China through its subsidiaries.


 

Investment Theme

 

First quarter net profit of 1.145 billion yuan rose 28%.

The number of patients has grown strongly. It is expected that the Group's profit growth will be stable in the first half of this year, and the national drug centralized purchasing policy will have limited impact on its revenue growth this year and next.

It is believed that Sinopharm's acquisition of Chinese scientific equipment to enter the fast-growing equipment distribution market is believed to help promote the Group's future growth.

By the end of 2018, the pharmaceutical retail business had covered 229 cities in 30 provinces across the country, with a total of 5,183 pharmacies, an increase of 740 over the same period last year.

Sinopharm has fallen to the lower limit of 30 yuan in the past three years. Considering the impact of digesting the two-vote system and increasing market share, the price-earnings ratio is only 11 times the lowest in 3 years, even if there is uncertainty in the purchase of 7+4, downward The risk of a breakthrough is not great.


 

Recommendation

Buy Price: 30.4 Target Price: 36 Cut Loss: 28.5

本人李乐雯为证监会持牌人士。截至本评论文章发表日止,本人及/或其有联系者并无持有全部提及之证券的所有相关财务权益

 

 

研究报告由辉立证券集团旗下于香港证监会持牌的辉立证券(香港)有限公司及/或辉立商品有限公司(「辉立」)所发报。本文所包含的资料均为辉立从相信为准确的来源搜集。辉立对有关报告所引致之任何损失或亏损概不负责。本报告所载的资料只供参考用途,并没有法律约束力,亦不构成投资建议,邀约,购入,出售任何产品。
投资涉及风险,有可能损失投资本金。你应该咨询专业人士,就本身的投资经验,财务状况,个人目标及风险取向,以提供投资意见。各类产品的风立,请参阅本公司网页http://www.phillip.com.hk「风险披露声明」。
辉立(或其雇员)可能持有本文所述有关的投资产品。此外,辉立(或任何附属公司)随时可能替向报告内容所述及的公司提供服务,招揽或业务往来。
以上资料为辉立拥有并受版权及知识产法保护。除非事先得到辉立明确书面批准,否则不应复制,散播或发布。
返回页首
联络我们
请即联络你的客户主任或致电我们。
研究部
电话 : (852) 2277 6846
传真 : (852) 2277 6565
电邮 : businessenquiry@phillip.com.hk

查询及支援
分行资料
投诉程序
查数网
登入
黄师傅每日讲股
研究部快讯
免费订阅
联络我们